Skeletal Diseases & Injuries
Arthritis
Arthritis is caused by inflammation in your joints. It causes pain and stiffness in affected joints, which usually worsens with age. There are two common forms of arthritis osteoarthritis and rheumatoid arthritis.
Osteoarthritis is the most common form of arthritis that occurs when cartilage, the connective tissue found between bones, breaks down. Rheumatoid arthritis on the other hand is an autoimmune disease, when the immune system attacks and destroys healthy tissue. In people with rheumatoid arthritis, the immune system attacks and breaks down the smooth lining in a joint (called the synovium) causing pain and inflammation.
Due to their regenerative capabilities stem cells are being explored for treating arthritis. The hope is stem cells can regenerate the tissues that are affected by arthritis.
| TRIAL HYPOTHESIS | CLINICAL TRIAL ID |
|---|---|
| Looking at the safety and efficacy of allogeneic (from a donor) mesenchymal stem cell infusion to treat new onset Rheumatoid Arthritis. |
NCT03186417
National Institute of Arthritis and Musculoskeletal and Skin Diseases, USA |
| Can allogeneic umbilical tissue-derived stem cells be used to induce remission of rheumatoid arthritis in patients that don’t respond to standard anti-rheumatoid drug therapy? |
NCT01985464
Stem Cell Institute, Panama |
| Exploring the use of autologous adipose-derived mesenchymal stem cells (HD-adMSCs) as a possible treatment for rheumatoid arthritis. |
NCT03691909
Hope Bioscience, Texas, USA |
| Looking at the safety and efficacy of allogeneic (from a donor) mesenchymal stem cell infusion to treat new onset Rheumatoid Arthritis. |
NCT03186417
National Institute of Arthritis and Musculoskeletal and Skin Diseases, USA |
| Safety and effectiveness of using amniotic and umbilical cord tissue to treat the following conditions: orthopaedic, neurological, urologic, autoimmune, renal, cardiac and pulmonary. |
NCT03899298
R3 Stem Cell, USA |
| Tolerability of umbilical cord tissue derived mesenchymal stem cell product BX-U001 for treating refractory rheumatoid arthritis |
NCT03828344
Baylx Inc, California |
| How does implanting allogeneic mesenchymal stem cells derived umbilical cord Wharton’s Jelly influence the pain and functioning in patients with knee osteoarthritis? |
NCT03337243
Scott Medical Health Center, Pittsburgh, Pennsylvania |
| Is there a maximum tolerated dose umbilical cord derived mesenchymal stem cells that can be used to treat knee osteoarthritis? |
NCT03357770
Peking University People’s Hospital |
| Can allogeneic umbilical cord mesenchymal stem cells be used to manage osteoarthritis? |
NCT03800810
Indonesia University |
| Multicenter trial of stem cell therapy for osteoarthritis |
NCT03818737
Emory University |
Spinal Cord Injury
Damage to the spinal cord, which changes it functions either temporarily or permanently results in spinal cord injuries. Depending on where the injury happens it can be classified a complete injury, where all sensation and muscle function is lost, or incomplete, where some nerve signals can travel past the injured area of the spinal cord. Common symptoms associated with spinal cord injuries include loss of sensation and muscle function to part of the body below the level of injury.
In 2019, Japan became the first country in the world to approve using stem cells to treat spinal cord injuries.
| TRIAL HYPOTHESIS | CLINICAL TRIAL ID |
|---|---|
| Exploring the safety and effectiveness of injecting allogeneic (from donor) umbilical cord derived mesenchymal stem cells into the spinal canal to treat patients with late stage chronic spinal cord injury. |
NCT03505034
West China Hospital & Shanghai East Hospital |
| Exploring the safety and effectiveness of injecting allogeneic (from donor) umbilical cord derived mesenchymal stem cells into the spinal canal to treat patients with sub-acute spinal cord injury. |
NCT03521336
West China Hospital & Shanghai East Hospital |
| Exploring the safety and effectiveness of injecting allogeneic (from donor) umbilical cord derived mesenchymal stem cells into the spinal canal to treat patients with early stage chronic spinal cord injury. |
NCT03521323
West China Hospital & Shanghai East Hospital |
| Can mesenchymal stem cells derived from fat tissue be safely administered into the cerebrospinal fluid (CSF) of patients with spinal cord injury? |
NCT03308565
Mayo Clinic, USA |
| Safety study of transplanting human spinal cord-derived neural stem cells to treat chronic spinal cord injury. |
NCT01772810
Neuralstem Inc., Maryland, USA |
| Potential benefits of using autologous (from donor) bone marrow derived stem cells to treat spinal cord injury with impaired motor or sensory function. |
NCT03225625
The Healing Institute, Florida, USA |
| Safety and tolerability of FAB117-HC (product containing human allogeneic adipose derived adult mesenchymal stem cells expanded and pulsed by H2O2 in culture) administered at a single-time point to patients with spinal cord injury. |
NCT02917291
Histocell S.L., Spain |
| How does direct transplantation (through surgery) of bone marrow-derived mesenchymal stem cell (cellgram-spine) affect injured spinal cords? |
NCT01676441
Pharmicell Co., Ltd., South Korea |
| Use of autologous (from patient) bone marrow mesenchymal stem cell transplant to treat patients with chronic and complete spinal cord injury. |
NCT02574585
Hospital Sao Rafael, Brazil |
Cartilage Repair
Cartilage is connective tissue that provides rubber-like protection to the ends of our bones at the joints. It’s also a structural component of the ear, the nose, airways, disks in our spinal cord and the rib cage. It is made of specialized cells known as chondrocytes.
When the cartilage between bones wear off it can lead to conditions like osteoarthritis and damage to joints. Stem cells are being looked as a potential therapy to induce regeneration of cartilage.
| TRIAL HYPOTHESIS | CLINICAL TRIAL ID |
|---|---|
| The efficacy and safety of transplanting umbilical cord mesenchymal stem cells in patients with knee cartilage damage. |
NCT02776943
South China Research Center for Stem Cell and Regenerative Medicine |
| The efficacy and safety of using umbilical cord mesenchymal stem cells to treat articular cartilage defect of the knee. |
NCT02291926
The Fifth Affiliated Hospital of Guangzhou Medical University, China |
| Study of allogeneic-unrelated umbilical cord blood-derived mesenchymal stem cell product (Cartistem®) in patients with articular cartilage defect or injury. |
NCT01041001
Medipost Co Ltd., South Korea |
| A long term follow-up study looking at the safety and effectiveness of CARTISTEM®, in repair of cartilage injury or defects, compared with microfracture. |
NCT01626677
Medipost Co Ltd., South Korea |
A Precious Gift of a Lifetime
Registering for stem cell banking takes only a few minutes.
A Precious Gift of a Lifetime
Registering for stem cell banking takes only a few minutes.
